Quote:

---

If the COVID indication shows efficacy in a relatively timely manner, I can see the SP over $4.

---

This is binary.

I think we've already seen efficacy, if only anecdotal.

However, if you are saying post-FDA approval we'll see the SP over $4 -- then I would have to respectfully disagree.

If leronlimab receives COVID approval, I anticipate $6-12 based on irrational exuberance alone (not based on a thoughtful analysis of the top line revenue generated from that indication, nor the net income that results).